Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman Sells 3,495 Shares

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 3,495 shares of Phreesia stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $24.88, for a total transaction of $86,955.60. Following the sale, the general counsel now directly owns 116,296 shares of the company’s stock, valued at $2,893,444.48. This represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Phreesia Price Performance

PHR stock opened at $25.16 on Friday. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -17.12 and a beta of 0.98. The firm’s 50-day moving average price is $20.81 and its two-hundred day moving average price is $21.96. The company has a current ratio of 1.74, a quick ratio of 1.77 and a debt-to-equity ratio of 0.04. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $29.16.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.04. The company had revenue of $106.80 million for the quarter, compared to analysts’ expectations of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. Phreesia’s quarterly revenue was up 16.6% on a year-over-year basis. During the same period last year, the firm earned ($0.58) earnings per share. As a group, equities analysts predict that Phreesia, Inc. will post -1.16 earnings per share for the current year.

Hedge Funds Weigh In On Phreesia

Hedge funds and other institutional investors have recently made changes to their positions in the business. International Assets Investment Management LLC boosted its holdings in Phreesia by 2,179.7% in the third quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock valued at $33,000 after acquiring an additional 1,395 shares in the last quarter. nVerses Capital LLC lifted its position in shares of Phreesia by 76.5% in the 2nd quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock worth $64,000 after purchasing an additional 1,300 shares during the period. Lombard Odier Asset Management USA Corp purchased a new stake in shares of Phreesia in the 2nd quarter worth about $202,000. Point72 DIFC Ltd purchased a new position in shares of Phreesia during the second quarter valued at about $209,000. Finally, XTX Topco Ltd bought a new position in Phreesia in the third quarter worth about $247,000. Institutional investors own 92.10% of the company’s stock.

Analyst Upgrades and Downgrades

PHR has been the topic of a number of research reports. JMP Securities restated a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a research report on Tuesday, December 10th. Needham & Company LLC restated a “buy” rating and issued a $29.00 target price on shares of Phreesia in a research report on Tuesday, December 10th. Royal Bank of Canada reiterated a “sector perform” rating and set a $23.00 price target on shares of Phreesia in a research report on Friday, September 27th. DA Davidson restated a “buy” rating and issued a $32.00 price objective on shares of Phreesia in a report on Thursday, September 5th. Finally, JPMorgan Chase & Co. increased their target price on shares of Phreesia from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Monday, September 9th. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, Phreesia currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.33.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.